Repare Therapeutics (RPTX) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RPTX shares.
View RPTX analyst ratings or view top-rated stocks.

4 brokerages have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price forecasts range from $14.00 to $28.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts.

Repare Therapeutics' stock was trading at $14.71 at the beginning of the year. Since then, RPTX stock has decreased by 13.7% and is now trading at $12.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our RPTX earnings forecast.

Repare Therapeutics Inc. (NASDAQ:RPTX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.55. The company had revenue of $30.25 million for the quarter, compared to the consensus estimate of $7.28 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 1.14% and a negative net margin of 1.85%.

ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AmerisourceBergen (ABC), AES (AES), Autodesk (ADSK) and

(RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Repare Therapeutics trades on the NASDAQ under the ticker symbol "RPTX."

Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (6.29%), ARK Investment Management LLC (6.24%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), BlackRock Inc. (0.74%), Renaissance Technologies LLC (0.35%) and Bank of Montreal Can (0.28%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley.
View institutional ownership trends.

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RPTX stock can currently be purchased for approximately $12.70.

Repare Therapeutics (NASDAQ:RPTX) has a market capitalization of $534.54 million and generates $131.83 million in revenue each year. The company earns $-29,050,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

The company employs 180 workers across the globe.

Repare Therapeutics' mailing address is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. The official website for the company is www.reparerx.com. The company can be reached via phone at 857-412-7018 or via email at investor@reparerx.com.